Shopping Cart 0
Cart Subtotal
USD 0

Cancer Research UK - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Cancer Research UK (CRUK) is a research institution which offers clinical research services to treat cancer. The institute offers research services for womb cancer, lung cancer, bladder cancer, bone cancer, bowel cancer, brain tumours, breast cancer, carcinoid, cervical cancer, children's cancer, choriocarcinoma, chronic lymphocytic leukaemia, chronic myeloid leukaemia, colon cancer, colorectal cancer, endometrial cancer, eye cancer, gallbladder cancer and gastric cancer among others. CRUK cancer treatment services comprises of symptoms research, screening, tests, treatment and clinical trial services. The institute also conducts research in the areas of Cancer biology, Cancer drugs, Clinical trials, Radiotherapy, Immunotherapy among others. CRUK is headquartered in London, the UK.

Cancer Research UK-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 7

List of Figures 8

Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Cancer Research UK, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10

Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12

Cancer Research UK, Medical Devices Deals, 2012 to YTD 2018 13

Cancer Research UK, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Cancer Research UK, Pharmaceuticals & Healthcare, Deal Details 19

Venture Financing 19

GammaDelta Therapeutics Raises Funds through Seed Financing 19

ADC Therapeutics To Raise USD 50 Million In Venture Financing 20

Partnerships 22

Cancer Research Technology Enters into Partnership with Celgene 22

Scancell and Cancer Research UK Enter into Agreement 23

Cancer Research UK and Biotecnol Enter into Agreement 24

Cancer Research Technology Enters into Agreement with Merck 25

Tusk Therapeutics Enters into Agreement with University College London and Cancer Research Technology 26

MRC Technology, Cancer Research UK and Cancer Research Technology Enter into Partnership 27

Cancer Research UK Enters into Agreement with Bicycle Therapeutics 28

Cancer Research UK, Cancer Research Technology to Enter into Agreement with TYG Oncology 29

Merck Sharp & Dohme, Verastem and Cancer Research UK Enter into Agreement 30

Artios Pharma Research Agreement with Cancer Research Technology 31

CiMaas Enters into Agreement with Cancer Research Technology and University of Copenhagen 32

Cell Therapy Catapult Enters into Joint venture Agreement with University of Birmingham and Cancer Research Technology 33

Cancer Research UK Enters into Research Agreement with OHSU Knight Cancer Institute 34

Monopar Therapeutics Enters into Agreement with Cancer Research UK and Cancer Research Technology 35

Medivir Enters into Development Agreement with Cancer Research Technology 36

BioInvent And CRT Enter Into Research Agreement With University Of Southampton 37

Cancer Research UK Forms Joint Venture with MedImmune 38

Cancer Research and Cancer Research Technology Enter into Co-Development Agreement with Astellas Pharma 39

Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 40

Cancer Research UK Enters Into Co-Development Agreement With AstraZeneca 42

Cancer Research UK And Eli Lilly Enter Into Agreement To Discover Cancer Treatments 43

GlaxoSmithKline Enters Into Agreement With Cancer Research Technology And University of Manchester For Cancer Drugs 44

HitGen Enters into Drug Discovery Agreement with Cancer Research UK and Cancer Research Technology 45

Cancer Research Technology Enters Into Agreement With Nuevolution For Anti-Cancer Drug Molecule Discovery 46

Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs 47

Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 48

Forma Therapeutics Expands Discovery Agreement with Cancer Research Technology 49

Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 50

Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 51

Cancer Research UK Enters Into Co-Development Agreement With Lorus To Develop Cancer Drug 52

Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 54

Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 56

BioInvent And Cancer Research Technology Enter Into Co-Development Agreement With Queen Mary, University of London 58

Licensing Agreements 59

Merck Enters into Licensing Agreement with Institute of Cancer Research and Cancer Research UK 59

Glythera Enters into Licensing Agreement with Cancer Research UK 60

Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement with HitGen 61

Tusk Therapeutics Enters into Licensing Agreement with University College London and Cancer Research Technology 62

Amplia Therapeutics Enters into Licensing Agreement with Cancer Research Technology 63

Achilles Therapeutics Receives Rights to Develop Immunotherapies for Cancer 64

Storm Therapeutics Receives Intellectual Property Rights from University of Cambridge and Cancer Research UK 65

Cancer Research Technology Enters into Licensing Agreement with Pangaea Biotech 66

Merck Enters into Licensing Agreement with Cancer Research Technology 67

Nemucore Medical Innovations Enters into Licensing Agreement with Cancer Research Technology 68

Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 69

Cancer Research UK Enters into Licensing Agreement with Amgen 70

Immatics Biotech, Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement 71

Alchemia Enters Into Licensing Agreement With Cancer Research Technology For FAK Inhibitors 72

Cancer Research Technology Enters into Licensing Agreement with Cancer Therapeutics CRC 73

Artios Pharma Enters into Licensing Agreement with Cancer Research Technology 74

BioInvent Enters into Licensing Agreement with University of Southampton and Cancer Research Technology 75

Epistem Holdings and CRT Enter into Licensing Agreement with Newcastle University 76

Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 77

Equity Offering 79

iOnctura Spin Out from Merck and Cancer Research Technology 79

Cancer Research UK-Key Competitors 80

Cancer Research UK-Key Employees 81

Cancer Research UK-Locations And Subsidiaries 82

Head Office 82

Other Locations & Subsidiaries 82

Joint Venture 82

Recent Developments 83

Strategy And Business Planning 83

Sep 19, 2018: Cancer Research UK launches new research hub for biotherapeutics 83

Corporate Communications 84

Jun 08, 2018: Cancer Research UK Appoints Tony Hickson As New chief business officer 84

Government and Public Interest 85

Sep 20, 2018: European cancer research gets GBP30 million vote of confidence 85

Sep 07, 2018: International collaboration brings USD 9.6 million grant to Colorado 87

Sep 05, 2018: Discovering better treatments for children with brain tumours 88

Aug 30, 2018: Engineered cell therapy given initial 'no' for NHS in England 90

Aug 24, 2018: Improving brain tumour diagnosis to make treatment personal 91

Aug 21, 2018: Scientists discover first step towards finding a new, targeted lung cancer treatment 94

Aug 16, 2018: Chemical shows promise at killing glioblastoma cells in mouse studies 95

Jul 31, 2018: Piecing together brain tumour biology to design more effective drugs 96

Jul 25, 2018: Protein discovery may explain why some patients develop resistance to new class of anti-cancer drugs 99

Jul 25, 2018: Obesity at record high in children aged 10-11 years 101

Jul 18, 2018: Boys should be given HPV jab, says vaccine committee. Here's what happens next 102

Jul 16, 2018: Older people and cancer: how research could personalise treatment plans and care 104

Jul 05, 2018: CRUK awards Bristol researcher GBP1.4 million to investigate cancer growth containment 107

Jul 02, 2018: Teamwork between cells fuels aggressive childhood brain tumour 108

Jul 02, 2018: Cell 'chatter' discovery could open clinical trial opportunity for fatal childhood brain tumour 109

Jun 28, 2018: MAP Congress 2018: Interpreting Molecular Alterations for Clinical Practice 111

Jun 06, 2018: Funding boost for Imperial researchers aiming to stop bowel cancer 112

Jun 04, 2018: Taking aspirin and anti-acid reflux medication prevents oesophageal cancer in high risk patients 113

May 21, 2018: Infection theory could explain cause of common childhood leukaemia, says scientist 114

May 17, 2018: Six months of Herceptin could be as effective as 12 months for some women with HER2 positive breast cancer 116

May 16, 2018: Six months of breast cancer treatment 'could be as effective as 12' in some women with early stage disease 118

May 14, 2018: Brain tumour funding boost following death of Tessa Jowell 119

May 11, 2018: Study paves the way for better treatment of prostate cancer 121

May 01, 2018: GBP18 million fund to tackle six biggest themes in brain tumour research launched today 123

May 01, 2018: A better understanding of brain tumour biology will bring new treatments 125

Apr 24, 2018: Six in seven women at high risk of breast cancer shun tamoxifen as a preventative measure 126

Apr 12, 2018: Piecing together kidney cancer evolution 127

Apr 12, 2018: 'Killer' kidney cancers identified by studying their evolution 130

Apr 09, 2018: Researchers discover 40 genes involved in early development of myeloma 132

Mar 28, 2018: Life Science Leaders Gather at Medidata NEXT Basel and Frankfurt to Examine New Opportunities to Improve Clinical Development and Better Patient Lives 133

Mar 28, 2018: Colon cancer chemo could be halved after surgery 134

Mar 06, 2018: Overdiagnosis: when finding cancer can do more harm than good 135

Mar 04, 2018: Finding common ground with arthritis could help cancer patients 138

Feb 22, 2018: Growing replica tumours in the lab could personalise drug treatment for each patient 140

Feb 15, 2018: Cancer Research UK to invest GBP45 million in clinical trials 143

Feb 15, 2018: Baylor team shortlisted for Cancer Research UK grants 144

Feb 07, 2018: Scientists halt breast cancer spread 145

Feb 06, 2018: Major research project launched to crack aspirin's anti-cancer properties 146

Feb 06, 2018: Research projected launched to crack aspirin's anti-cancer properties 147

Feb 06, 2018: Prof Peter McHugh awarded CRUK grant to investigate how cancer cells resist treatment 148

Jan 25, 2018: Building new models to study glioblastoma: Professor Steven Pollard 149

Jan 22, 2018: Brain cancer research to receive GBP45 million funding 151

Jan 11, 2018: Breast cancer survival not affected by faulty BRCA genes 152

Jan 03, 2018: New research shows how alcohol damages DNA and increases cancer risk 153

Jan 03, 2018: Virus could treat brain tumours by boosting immune system 154

Nov 30, 2017: Tackling 'undruggable' genes in lung and pancreatic cancers is this researcher's life 157

Nov 30, 2017: Immune-boosting antibody combination could improve lymphoma survival 161

Nov 03, 2017: More women than men are diagnosed with bowel cancer as an emergency despite extra GP visits 162

Nov 02, 2017: Gut bacteria may influence response to cancer immunotherapy 163

Nov 02, 2017: Scientists awarded GBP1.5m for pioneering bowel cancer research 164

Nov 01, 2017: Alternative cancer therapies: the potential impact on survival 165

Oct 27, 2017: Safety of gene therapy for brain tumours tested in early trial 168

Oct 26, 2017: GBP800K Boost for Queen's University Researchers to Improve Bowel Cancer Treatment 169

Oct 24, 2017: Some aggressive ovarian cancers start in the fallopian tubes, not the ovaries 171

Oct 24, 2017: Internal radiotherapy: tackling cancer from within 172

Oct 18, 2017: Researchers "drug the undruggable" through unique collaboration 174

Oct 05, 2017: Some cancer drugs approved in Europe might not have sufficient evidence of survival benefits, says study 175

Sep 26, 2017: Pelvis-targeting radiotherapy safe for prostate cancer patients 177

Sep 17, 2017: GBP2million award for cancer researcher 178

Sep 15, 2017: New funding to unite transatlantic forces for the early detection of cancer 179

Sep 08, 2017: Viruses may boost immunotherapy success 180

Sep 08, 2017: Targeted drug helps keep some advanced ovarian cancers at bay 182

Sep 08, 2017: Two treatments for advanced prostate cancer bring equal benefits 183

Sep 05, 2017: New approach could better predict breast cancer risk due to family history 184

Aug 30, 2017: Early detection of cancer highlighted in new life sciences industrial strategy 186

Aug 22, 2017: Studies highlight 'potential new targets for immunotherapy' 187

Aug 17, 2017: New Way To Empower The Immune System To Detect And Kill Cancer 188

Aug 03, 2017: Scientists deliver knock-out blow to multiple cancers 189

Aug 02, 2017: Targeted radiotherapy limits side effects of breast cancer treatment 190

Jul 13, 2017: Scientists make breakthrough in reversing treatment resistance in blood cancer patients 192

Jun 19, 2017: Discovery could guide immunotherapy for lung cancer 194

Apr 19, 2017: CRT pioneer fund, Cancer Research UK and NCI collaborate to boost research against the 'undruggable' RAS 195

Feb 10, 2017: U.S. Scientists Receive Inaugural USD 87 Million Grand Challenge Awards To Accelerate Global Progress To Beat Cancer Sooner 196

Feb 01, 2017: Cancer Research: Big data brings breast cancer research forwards by 'decades' 197

Jan 16, 2017: Ludwig Study Reveals Why Cancer Cells Spread Within The Body 198

Product News 200

Nov 24, 2017: Experimental drug trial seeks to improve treatment for head and neck cancer 200

Sep 06, 2017: Keyhole oesophageal cancer surgery as good as more invasive operations 201

Jul 11, 2018: Brain tumour chemotherapy now available to even more NHS patients 202

Jun 20, 2018: Study finds drug reduces hearing loss in children with liver cancer 204

Jun 06, 2017: New chemotherapy approach offers breast cancer patients a better quality of life 205

Apr 30, 2018: Targeting chemotherapy with genetic testing provides effective treatment for women with aggressive breast cancer 206

Apr 20, 2018: UK to align with EU clinical trial rules after Brexit 209

Feb 16, 2018: Breast cancer relapse tests vary in accuracy 210

Other Significant Developments 211

Sep 17, 2018: London biotherapeutics powerhouse launched by Cancer Research UK 211

Sep 14, 2018: Making chemotherapy kinder for childhood leukaemia 213

Aug 31, 2018: Artificial intelligence can predict how cancers will evolve and spread 215

Jul 20, 2018: Mixing complementary therapy with standard cancer treatment could affect survival 217

Jul 12, 2018: Brain tumour surgery dye now available to more NHS patients 220

Jun 28, 2018: Unlocking new insight into brain tumours using neuroscience 221

Jun 04, 2018: Chemoradiotherapy before surgery may extend lives of pancreatic cancer patients 224

Jun 04, 2018: Chemo combo could help pancreatic cancer patients live longer after surgery 226

Jan 31, 2018: NHS radiotherapy changes could see more patients having modern treatment 228

Appendix 230

Methodology 230

About GlobalData 230

Contact Us 230

Disclaimer 230


List Of Figure

List of Figures

Cancer Research UK, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Cancer Research UK, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 10

Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12

Cancer Research UK, Medical Devices Deals, 2012 to YTD 2018 13


List Of Table

List of Tables

Cancer Research UK, Pharmaceuticals & Healthcare, Key Facts 2

Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Cancer Research UK, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10

Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Cancer Research UK, Deals By Therapy Area, 2012 to YTD 2018 12

Cancer Research UK, Medical Devices Deals, 2012 to YTD 2018 13

Cancer Research UK, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

GammaDelta Therapeutics Raises Funds through Seed Financing 19

ADC Therapeutics To Raise USD 50 Million In Venture Financing 20

Cancer Research Technology Enters into Partnership with Celgene 22

Scancell and Cancer Research UK Enter into Agreement 23

Cancer Research UK and Biotecnol Enter into Agreement 24

Cancer Research Technology Enters into Agreement with Merck 25

Tusk Therapeutics Enters into Agreement with University College London and Cancer Research Technology 26

MRC Technology, Cancer Research UK and Cancer Research Technology Enter into Partnership 27

Cancer Research UK Enters into Agreement with Bicycle Therapeutics 28

Cancer Research UK, Cancer Research Technology to Enter into Agreement with TYG Oncology 29

Merck Sharp & Dohme, Verastem and Cancer Research UK Enter into Agreement 30

Artios Pharma Research Agreement with Cancer Research Technology 31

CiMaas Enters into Agreement with Cancer Research Technology and University of Copenhagen 32

Cell Therapy Catapult Enters into Joint venture Agreement with University of Birmingham and Cancer Research Technology 33

Cancer Research UK Enters into Research Agreement with OHSU Knight Cancer Institute 34

Monopar Therapeutics Enters into Agreement with Cancer Research UK and Cancer Research Technology 35

Medivir Enters into Development Agreement with Cancer Research Technology 36

BioInvent And CRT Enter Into Research Agreement With University Of Southampton 37

Cancer Research UK Forms Joint Venture with MedImmune 38

Cancer Research and Cancer Research Technology Enter into Co-Development Agreement with Astellas Pharma 39

Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 40

Cancer Research UK Enters Into Co-Development Agreement With AstraZeneca 42

Cancer Research UK And Eli Lilly Enter Into Agreement To Discover Cancer Treatments 43

GlaxoSmithKline Enters Into Agreement With Cancer Research Technology And University of Manchester For Cancer Drugs 44

HitGen Enters into Drug Discovery Agreement with Cancer Research UK and Cancer Research Technology 45

Cancer Research Technology Enters Into Agreement With Nuevolution For Anti-Cancer Drug Molecule Discovery 46

Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs 47

Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 48

Forma Therapeutics Expands Discovery Agreement with Cancer Research Technology 49

Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 50

Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 51

Cancer Research UK Enters Into Co-Development Agreement With Lorus To Develop Cancer Drug 52

Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 54

Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 56

BioInvent And Cancer Research Technology Enter Into Co-Development Agreement With Queen Mary, University of London 58

Merck Enters into Licensing Agreement with Institute of Cancer Research and Cancer Research UK 59

Glythera Enters into Licensing Agreement with Cancer Research UK 60

Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement with HitGen 61

Tusk Therapeutics Enters into Licensing Agreement with University College London and Cancer Research Technology 62

Amplia Therapeutics Enters into Licensing Agreement with Cancer Research Technology 63

Achilles Therapeutics Receives Rights to Develop Immunotherapies for Cancer 64

Storm Therapeutics Receives Intellectual Property Rights from University of Cambridge and Cancer Research UK 65

Cancer Research Technology Enters into Licensing Agreement with Pangaea Biotech 66

Merck Enters into Licensing Agreement with Cancer Research Technology 67

Nemucore Medical Innovations Enters into Licensing Agreement with Cancer Research Technology 68

Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 69

Cancer Research UK Enters into Licensing Agreement with Amgen 70

Immatics Biotech, Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement 71

Alchemia Enters Into Licensing Agreement With Cancer Research Technology For FAK Inhibitors 72

Cancer Research Technology Enters into Licensing Agreement with Cancer Therapeutics CRC 73

Artios Pharma Enters into Licensing Agreement with Cancer Research Technology 74

BioInvent Enters into Licensing Agreement with University of Southampton and Cancer Research Technology 75

Epistem Holdings and CRT Enter into Licensing Agreement with Newcastle University 76

Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 77

iOnctura Spin Out from Merck and Cancer Research Technology 79

Cancer Research UK, Key Competitors 80

Cancer Research UK, Key Employees 81

Cancer Research UK, Subsidiaries 82

Cancer Research UK, Joint Venture 82

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Cancer Research UK, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Cancer Research UK (CRUK) is a research institution which offers clinical research services to treat cancer. The institute offers research services for womb cancer, lung cancer, bladder cancer, bone cancer, bowel cancer, brain tumours, breast cancer, carcinoid, cervical cancer, children's cancer, choriocarcinoma, chronic lymphocytic leukaemia, chronic myeloid leukaemia, colon cancer, colorectal cancer, endometrial cancer, eye cancer, gallbladder cancer and gastric cancer among others. CRUK cancer treatment services comprises of symptoms research, screening, tests, treatment and clinical trial services. The institute also conducts research in the areas of Cancer biology, Cancer drugs, Clinical trials, Radiotherapy, Immunotherapy among others. CRUK is headquartered in London, the UK.

Cancer Research UK-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 7

List of Figures 8

Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Cancer Research UK, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10

Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12

Cancer Research UK, Medical Devices Deals, 2012 to YTD 2018 13

Cancer Research UK, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Cancer Research UK, Pharmaceuticals & Healthcare, Deal Details 19

Venture Financing 19

GammaDelta Therapeutics Raises Funds through Seed Financing 19

ADC Therapeutics To Raise USD 50 Million In Venture Financing 20

Partnerships 22

Cancer Research Technology Enters into Partnership with Celgene 22

Scancell and Cancer Research UK Enter into Agreement 23

Cancer Research UK and Biotecnol Enter into Agreement 24

Cancer Research Technology Enters into Agreement with Merck 25

Tusk Therapeutics Enters into Agreement with University College London and Cancer Research Technology 26

MRC Technology, Cancer Research UK and Cancer Research Technology Enter into Partnership 27

Cancer Research UK Enters into Agreement with Bicycle Therapeutics 28

Cancer Research UK, Cancer Research Technology to Enter into Agreement with TYG Oncology 29

Merck Sharp & Dohme, Verastem and Cancer Research UK Enter into Agreement 30

Artios Pharma Research Agreement with Cancer Research Technology 31

CiMaas Enters into Agreement with Cancer Research Technology and University of Copenhagen 32

Cell Therapy Catapult Enters into Joint venture Agreement with University of Birmingham and Cancer Research Technology 33

Cancer Research UK Enters into Research Agreement with OHSU Knight Cancer Institute 34

Monopar Therapeutics Enters into Agreement with Cancer Research UK and Cancer Research Technology 35

Medivir Enters into Development Agreement with Cancer Research Technology 36

BioInvent And CRT Enter Into Research Agreement With University Of Southampton 37

Cancer Research UK Forms Joint Venture with MedImmune 38

Cancer Research and Cancer Research Technology Enter into Co-Development Agreement with Astellas Pharma 39

Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 40

Cancer Research UK Enters Into Co-Development Agreement With AstraZeneca 42

Cancer Research UK And Eli Lilly Enter Into Agreement To Discover Cancer Treatments 43

GlaxoSmithKline Enters Into Agreement With Cancer Research Technology And University of Manchester For Cancer Drugs 44

HitGen Enters into Drug Discovery Agreement with Cancer Research UK and Cancer Research Technology 45

Cancer Research Technology Enters Into Agreement With Nuevolution For Anti-Cancer Drug Molecule Discovery 46

Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs 47

Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 48

Forma Therapeutics Expands Discovery Agreement with Cancer Research Technology 49

Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 50

Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 51

Cancer Research UK Enters Into Co-Development Agreement With Lorus To Develop Cancer Drug 52

Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 54

Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 56

BioInvent And Cancer Research Technology Enter Into Co-Development Agreement With Queen Mary, University of London 58

Licensing Agreements 59

Merck Enters into Licensing Agreement with Institute of Cancer Research and Cancer Research UK 59

Glythera Enters into Licensing Agreement with Cancer Research UK 60

Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement with HitGen 61

Tusk Therapeutics Enters into Licensing Agreement with University College London and Cancer Research Technology 62

Amplia Therapeutics Enters into Licensing Agreement with Cancer Research Technology 63

Achilles Therapeutics Receives Rights to Develop Immunotherapies for Cancer 64

Storm Therapeutics Receives Intellectual Property Rights from University of Cambridge and Cancer Research UK 65

Cancer Research Technology Enters into Licensing Agreement with Pangaea Biotech 66

Merck Enters into Licensing Agreement with Cancer Research Technology 67

Nemucore Medical Innovations Enters into Licensing Agreement with Cancer Research Technology 68

Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 69

Cancer Research UK Enters into Licensing Agreement with Amgen 70

Immatics Biotech, Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement 71

Alchemia Enters Into Licensing Agreement With Cancer Research Technology For FAK Inhibitors 72

Cancer Research Technology Enters into Licensing Agreement with Cancer Therapeutics CRC 73

Artios Pharma Enters into Licensing Agreement with Cancer Research Technology 74

BioInvent Enters into Licensing Agreement with University of Southampton and Cancer Research Technology 75

Epistem Holdings and CRT Enter into Licensing Agreement with Newcastle University 76

Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 77

Equity Offering 79

iOnctura Spin Out from Merck and Cancer Research Technology 79

Cancer Research UK-Key Competitors 80

Cancer Research UK-Key Employees 81

Cancer Research UK-Locations And Subsidiaries 82

Head Office 82

Other Locations & Subsidiaries 82

Joint Venture 82

Recent Developments 83

Strategy And Business Planning 83

Sep 19, 2018: Cancer Research UK launches new research hub for biotherapeutics 83

Corporate Communications 84

Jun 08, 2018: Cancer Research UK Appoints Tony Hickson As New chief business officer 84

Government and Public Interest 85

Sep 20, 2018: European cancer research gets GBP30 million vote of confidence 85

Sep 07, 2018: International collaboration brings USD 9.6 million grant to Colorado 87

Sep 05, 2018: Discovering better treatments for children with brain tumours 88

Aug 30, 2018: Engineered cell therapy given initial 'no' for NHS in England 90

Aug 24, 2018: Improving brain tumour diagnosis to make treatment personal 91

Aug 21, 2018: Scientists discover first step towards finding a new, targeted lung cancer treatment 94

Aug 16, 2018: Chemical shows promise at killing glioblastoma cells in mouse studies 95

Jul 31, 2018: Piecing together brain tumour biology to design more effective drugs 96

Jul 25, 2018: Protein discovery may explain why some patients develop resistance to new class of anti-cancer drugs 99

Jul 25, 2018: Obesity at record high in children aged 10-11 years 101

Jul 18, 2018: Boys should be given HPV jab, says vaccine committee. Here's what happens next 102

Jul 16, 2018: Older people and cancer: how research could personalise treatment plans and care 104

Jul 05, 2018: CRUK awards Bristol researcher GBP1.4 million to investigate cancer growth containment 107

Jul 02, 2018: Teamwork between cells fuels aggressive childhood brain tumour 108

Jul 02, 2018: Cell 'chatter' discovery could open clinical trial opportunity for fatal childhood brain tumour 109

Jun 28, 2018: MAP Congress 2018: Interpreting Molecular Alterations for Clinical Practice 111

Jun 06, 2018: Funding boost for Imperial researchers aiming to stop bowel cancer 112

Jun 04, 2018: Taking aspirin and anti-acid reflux medication prevents oesophageal cancer in high risk patients 113

May 21, 2018: Infection theory could explain cause of common childhood leukaemia, says scientist 114

May 17, 2018: Six months of Herceptin could be as effective as 12 months for some women with HER2 positive breast cancer 116

May 16, 2018: Six months of breast cancer treatment 'could be as effective as 12' in some women with early stage disease 118

May 14, 2018: Brain tumour funding boost following death of Tessa Jowell 119

May 11, 2018: Study paves the way for better treatment of prostate cancer 121

May 01, 2018: GBP18 million fund to tackle six biggest themes in brain tumour research launched today 123

May 01, 2018: A better understanding of brain tumour biology will bring new treatments 125

Apr 24, 2018: Six in seven women at high risk of breast cancer shun tamoxifen as a preventative measure 126

Apr 12, 2018: Piecing together kidney cancer evolution 127

Apr 12, 2018: 'Killer' kidney cancers identified by studying their evolution 130

Apr 09, 2018: Researchers discover 40 genes involved in early development of myeloma 132

Mar 28, 2018: Life Science Leaders Gather at Medidata NEXT Basel and Frankfurt to Examine New Opportunities to Improve Clinical Development and Better Patient Lives 133

Mar 28, 2018: Colon cancer chemo could be halved after surgery 134

Mar 06, 2018: Overdiagnosis: when finding cancer can do more harm than good 135

Mar 04, 2018: Finding common ground with arthritis could help cancer patients 138

Feb 22, 2018: Growing replica tumours in the lab could personalise drug treatment for each patient 140

Feb 15, 2018: Cancer Research UK to invest GBP45 million in clinical trials 143

Feb 15, 2018: Baylor team shortlisted for Cancer Research UK grants 144

Feb 07, 2018: Scientists halt breast cancer spread 145

Feb 06, 2018: Major research project launched to crack aspirin's anti-cancer properties 146

Feb 06, 2018: Research projected launched to crack aspirin's anti-cancer properties 147

Feb 06, 2018: Prof Peter McHugh awarded CRUK grant to investigate how cancer cells resist treatment 148

Jan 25, 2018: Building new models to study glioblastoma: Professor Steven Pollard 149

Jan 22, 2018: Brain cancer research to receive GBP45 million funding 151

Jan 11, 2018: Breast cancer survival not affected by faulty BRCA genes 152

Jan 03, 2018: New research shows how alcohol damages DNA and increases cancer risk 153

Jan 03, 2018: Virus could treat brain tumours by boosting immune system 154

Nov 30, 2017: Tackling 'undruggable' genes in lung and pancreatic cancers is this researcher's life 157

Nov 30, 2017: Immune-boosting antibody combination could improve lymphoma survival 161

Nov 03, 2017: More women than men are diagnosed with bowel cancer as an emergency despite extra GP visits 162

Nov 02, 2017: Gut bacteria may influence response to cancer immunotherapy 163

Nov 02, 2017: Scientists awarded GBP1.5m for pioneering bowel cancer research 164

Nov 01, 2017: Alternative cancer therapies: the potential impact on survival 165

Oct 27, 2017: Safety of gene therapy for brain tumours tested in early trial 168

Oct 26, 2017: GBP800K Boost for Queen's University Researchers to Improve Bowel Cancer Treatment 169

Oct 24, 2017: Some aggressive ovarian cancers start in the fallopian tubes, not the ovaries 171

Oct 24, 2017: Internal radiotherapy: tackling cancer from within 172

Oct 18, 2017: Researchers "drug the undruggable" through unique collaboration 174

Oct 05, 2017: Some cancer drugs approved in Europe might not have sufficient evidence of survival benefits, says study 175

Sep 26, 2017: Pelvis-targeting radiotherapy safe for prostate cancer patients 177

Sep 17, 2017: GBP2million award for cancer researcher 178

Sep 15, 2017: New funding to unite transatlantic forces for the early detection of cancer 179

Sep 08, 2017: Viruses may boost immunotherapy success 180

Sep 08, 2017: Targeted drug helps keep some advanced ovarian cancers at bay 182

Sep 08, 2017: Two treatments for advanced prostate cancer bring equal benefits 183

Sep 05, 2017: New approach could better predict breast cancer risk due to family history 184

Aug 30, 2017: Early detection of cancer highlighted in new life sciences industrial strategy 186

Aug 22, 2017: Studies highlight 'potential new targets for immunotherapy' 187

Aug 17, 2017: New Way To Empower The Immune System To Detect And Kill Cancer 188

Aug 03, 2017: Scientists deliver knock-out blow to multiple cancers 189

Aug 02, 2017: Targeted radiotherapy limits side effects of breast cancer treatment 190

Jul 13, 2017: Scientists make breakthrough in reversing treatment resistance in blood cancer patients 192

Jun 19, 2017: Discovery could guide immunotherapy for lung cancer 194

Apr 19, 2017: CRT pioneer fund, Cancer Research UK and NCI collaborate to boost research against the 'undruggable' RAS 195

Feb 10, 2017: U.S. Scientists Receive Inaugural USD 87 Million Grand Challenge Awards To Accelerate Global Progress To Beat Cancer Sooner 196

Feb 01, 2017: Cancer Research: Big data brings breast cancer research forwards by 'decades' 197

Jan 16, 2017: Ludwig Study Reveals Why Cancer Cells Spread Within The Body 198

Product News 200

Nov 24, 2017: Experimental drug trial seeks to improve treatment for head and neck cancer 200

Sep 06, 2017: Keyhole oesophageal cancer surgery as good as more invasive operations 201

Jul 11, 2018: Brain tumour chemotherapy now available to even more NHS patients 202

Jun 20, 2018: Study finds drug reduces hearing loss in children with liver cancer 204

Jun 06, 2017: New chemotherapy approach offers breast cancer patients a better quality of life 205

Apr 30, 2018: Targeting chemotherapy with genetic testing provides effective treatment for women with aggressive breast cancer 206

Apr 20, 2018: UK to align with EU clinical trial rules after Brexit 209

Feb 16, 2018: Breast cancer relapse tests vary in accuracy 210

Other Significant Developments 211

Sep 17, 2018: London biotherapeutics powerhouse launched by Cancer Research UK 211

Sep 14, 2018: Making chemotherapy kinder for childhood leukaemia 213

Aug 31, 2018: Artificial intelligence can predict how cancers will evolve and spread 215

Jul 20, 2018: Mixing complementary therapy with standard cancer treatment could affect survival 217

Jul 12, 2018: Brain tumour surgery dye now available to more NHS patients 220

Jun 28, 2018: Unlocking new insight into brain tumours using neuroscience 221

Jun 04, 2018: Chemoradiotherapy before surgery may extend lives of pancreatic cancer patients 224

Jun 04, 2018: Chemo combo could help pancreatic cancer patients live longer after surgery 226

Jan 31, 2018: NHS radiotherapy changes could see more patients having modern treatment 228

Appendix 230

Methodology 230

About GlobalData 230

Contact Us 230

Disclaimer 230


List Of Figure

List of Figures

Cancer Research UK, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Cancer Research UK, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 10

Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12

Cancer Research UK, Medical Devices Deals, 2012 to YTD 2018 13


List Of Table

List of Tables

Cancer Research UK, Pharmaceuticals & Healthcare, Key Facts 2

Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9

Cancer Research UK, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10

Cancer Research UK, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11

Cancer Research UK, Deals By Therapy Area, 2012 to YTD 2018 12

Cancer Research UK, Medical Devices Deals, 2012 to YTD 2018 13

Cancer Research UK, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

GammaDelta Therapeutics Raises Funds through Seed Financing 19

ADC Therapeutics To Raise USD 50 Million In Venture Financing 20

Cancer Research Technology Enters into Partnership with Celgene 22

Scancell and Cancer Research UK Enter into Agreement 23

Cancer Research UK and Biotecnol Enter into Agreement 24

Cancer Research Technology Enters into Agreement with Merck 25

Tusk Therapeutics Enters into Agreement with University College London and Cancer Research Technology 26

MRC Technology, Cancer Research UK and Cancer Research Technology Enter into Partnership 27

Cancer Research UK Enters into Agreement with Bicycle Therapeutics 28

Cancer Research UK, Cancer Research Technology to Enter into Agreement with TYG Oncology 29

Merck Sharp & Dohme, Verastem and Cancer Research UK Enter into Agreement 30

Artios Pharma Research Agreement with Cancer Research Technology 31

CiMaas Enters into Agreement with Cancer Research Technology and University of Copenhagen 32

Cell Therapy Catapult Enters into Joint venture Agreement with University of Birmingham and Cancer Research Technology 33

Cancer Research UK Enters into Research Agreement with OHSU Knight Cancer Institute 34

Monopar Therapeutics Enters into Agreement with Cancer Research UK and Cancer Research Technology 35

Medivir Enters into Development Agreement with Cancer Research Technology 36

BioInvent And CRT Enter Into Research Agreement With University Of Southampton 37

Cancer Research UK Forms Joint Venture with MedImmune 38

Cancer Research and Cancer Research Technology Enter into Co-Development Agreement with Astellas Pharma 39

Nuevolution Enters Into Agreement With Cancer Research Technology And Institute Of Cancer Research For Drug Discovery 40

Cancer Research UK Enters Into Co-Development Agreement With AstraZeneca 42

Cancer Research UK And Eli Lilly Enter Into Agreement To Discover Cancer Treatments 43

GlaxoSmithKline Enters Into Agreement With Cancer Research Technology And University of Manchester For Cancer Drugs 44

HitGen Enters into Drug Discovery Agreement with Cancer Research UK and Cancer Research Technology 45

Cancer Research Technology Enters Into Agreement With Nuevolution For Anti-Cancer Drug Molecule Discovery 46

Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs 47

Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 48

Forma Therapeutics Expands Discovery Agreement with Cancer Research Technology 49

Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 50

Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 51

Cancer Research UK Enters Into Co-Development Agreement With Lorus To Develop Cancer Drug 52

Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 54

Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 56

BioInvent And Cancer Research Technology Enter Into Co-Development Agreement With Queen Mary, University of London 58

Merck Enters into Licensing Agreement with Institute of Cancer Research and Cancer Research UK 59

Glythera Enters into Licensing Agreement with Cancer Research UK 60

Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement with HitGen 61

Tusk Therapeutics Enters into Licensing Agreement with University College London and Cancer Research Technology 62

Amplia Therapeutics Enters into Licensing Agreement with Cancer Research Technology 63

Achilles Therapeutics Receives Rights to Develop Immunotherapies for Cancer 64

Storm Therapeutics Receives Intellectual Property Rights from University of Cambridge and Cancer Research UK 65

Cancer Research Technology Enters into Licensing Agreement with Pangaea Biotech 66

Merck Enters into Licensing Agreement with Cancer Research Technology 67

Nemucore Medical Innovations Enters into Licensing Agreement with Cancer Research Technology 68

Basilea Pharma Enters into Licensing Agreement for Novel PanRAF Kinase Inhibitors 69

Cancer Research UK Enters into Licensing Agreement with Amgen 70

Immatics Biotech, Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement 71

Alchemia Enters Into Licensing Agreement With Cancer Research Technology For FAK Inhibitors 72

Cancer Research Technology Enters into Licensing Agreement with Cancer Therapeutics CRC 73

Artios Pharma Enters into Licensing Agreement with Cancer Research Technology 74

BioInvent Enters into Licensing Agreement with University of Southampton and Cancer Research Technology 75

Epistem Holdings and CRT Enter into Licensing Agreement with Newcastle University 76

Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 77

iOnctura Spin Out from Merck and Cancer Research Technology 79

Cancer Research UK, Key Competitors 80

Cancer Research UK, Key Employees 81

Cancer Research UK, Subsidiaries 82

Cancer Research UK, Joint Venture 82

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Cancer Research UK, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.